Official Title
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Brief Summary

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.


Drug: LY2503029

Administered orally.

Drug: LY3023414

Administered orally.

Eligibility Criteria

Inclusion Criteria:

- To be eligible patients must be currently receiving benefit in a concluded Lilly study
for a compound that has opened an addendum in the continued access protocol.

Exclusion Criteria:

- Patients must not be concurrently enrolled in any other type of medical research
judged not to be scientifically or medically compatible with this study.

Eligibility Gender
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
United States

UCLA Medical Center
Torrance, California, United States

Fort Wayne Oncology & Hematology
Fort Wayne, Indiana, United States

Sarah Cannon Cancer Center
Nashville, Tennessee, United States


There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST), Study Director
Eli Lilly and Company

Eli Lilly and Company
NCT Number